Europe approves guselkumab for children with plaque psoriasis

The European Medicines Agency approves guselkumab (TREMFYA) for children.

Published 16sem1 sourceNotableupdated 11sem
Lire en français
≈ 15s

The fact

This treatment targets moderate to severe plaque psoriasis in ages 6-17.

A therapeutic breakthrough for a chronic and often debilitating disease.

Click the link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
Follow topic →
Auto-synthesis from 1 media source · identified on July 31, 2026
← Back to home
Discover

Read more

All sante →